Artal Group’s Phathom Pharmaceuticals PHAT Stock Holding History

Artal Group’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-200,000	Closed	-$3.93M	–	144
2021 Q4	$3.93M	Buy	+200,000	New	+$4.71M	0.11%	113

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Artal Group's PHAT Position: Q1 2022 in Review

Artal Group sold out of Phathom Pharmaceuticals (PHAT) in Q1 2022, closing a stake of 200,000 shares — an estimated $3.93M sold.

Artal Group first reported a position in PHAT in Q4 2021 and held it in 1 quarter. The position peaked at $3.93M in Q4 2021. 82 funds tracked by Wall St. Rank hold PHAT as of Q1 2022.

Artal Group reported no remaining Phathom Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Artal Group sold 200,000 Phathom Pharmaceuticals shares in Q1 2022, an estimated $3.93M.
Artal Group first reported a position in Phathom Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Artal Group's Phathom Pharmaceuticals position peaked at $3.93M in Q4 2021.
82 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2022.

Based on Artal Group's 13F filing for Q1 2022, filed 12 May 2022.